{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:07:30Z","timestamp":1789380450993,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-026-12633-1","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:24:32Z","timestamp":1778873072000},"page":"7817-7827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-8719","authenticated-orcid":false,"given":"Chiara","family":"Bellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bicchierai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"de Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"di Naro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Vidali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolina","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermanno","family":"Vanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Visani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Vezzosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Orzalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Susini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Nori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"12633_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(20)30580-5","volume":"22","author":"P Dubsky","year":"2021","unstructured":"Dubsky P, Pinker K, Cardoso F et al (2021) Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol 22:e18\u2013e28","journal-title":"Lancet Oncol"},{"key":"12633_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","volume":"29","author":"CE Loo","year":"2011","unstructured":"Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660\u2013666","journal-title":"J Clin Oncol"},{"key":"12633_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"MBI Lobbes","year":"2013","unstructured":"Lobbes MBI, Prevos R, Smidt M et al (2013) The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 4:163\u2013175","journal-title":"Insights Imaging"},{"key":"12633_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P et al (2013) Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 105:321\u2013333","journal-title":"J Natl Cancer Inst"},{"key":"12633_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13244-024-01653-4","volume":"15","author":"F Sardanelli","year":"2024","unstructured":"Sardanelli F, Magni V, Rossini G, Kilburn-Toppin F, Healy NA, Gilbert FJ (2024) The paradox of MRI for breast cancer screening: high-risk and dense breasts-available evidence and current practice. Insights Imaging 15:96","journal-title":"Insights Imaging"},{"key":"12633_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ejca.2010.02.015","volume":"46","author":"F Sardanelli","year":"2010","unstructured":"Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296\u20131316","journal-title":"Eur J Cancer"},{"key":"12633_CR7","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.3390\/curroncol29110667","volume":"29","author":"A D\u2019Angelo","year":"2022","unstructured":"D\u2019Angelo A, Trombadori CML, Caprini F et al (2022) Efficacy and accuracy of using magnetic seed for preoperative non-palpable breast lesions localization: our experience with Magseed. Curr Oncol 29:8468\u20138474","journal-title":"Curr Oncol"},{"key":"12633_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41747-022-00280-2","volume":"6","author":"A Petrillo","year":"2022","unstructured":"Petrillo A, Di Giacomo R, Esposito E et al (2022) Preoperative localisation of nonpalpable breast lesions using magnetic markers in a tertiary cancer centre. Eur Radiol Exp 6:28","journal-title":"Eur Radiol Exp"},{"key":"12633_CR9","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1007\/s00330-023-10574-7","volume":"34","author":"S Schiaffino","year":"2024","unstructured":"Schiaffino S, Cozzi A, Clauser P et al (2024) Current use and future perspectives of contrast-enhanced mammography (CEM): a survey by the European Society of Breast Imaging (EUSOBI). Eur Radiol 34:5439\u20135450","journal-title":"Eur Radiol"},{"key":"12633_CR10","doi-asserted-by":"crossref","unstructured":"Bellini C, Susini T, Toncelli K et al (2025) Lesion conspicuity in contrast-enhanced mammography: a retrospective analysis of tumor characteristics. Cancers (Basel) 17:501","DOI":"10.3390\/cancers17030501"},{"key":"12633_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2214\/AJR.23.29337","volume":"221","author":"MBI Lobbes","year":"2023","unstructured":"Lobbes MBI, Essers BAB (2023) Cost-effectiveness of breast cancer staging modalities: point-contrast-enhanced mammography as an alternative to breast MRI for preoperative staging in patients with breast cancer. AJR Am J Roentgenol 221:434\u2013435","journal-title":"AJR Am J Roentgenol"},{"key":"12633_CR12","doi-asserted-by":"publisher","first-page":"W231","DOI":"10.2214\/AJR.16.17239","volume":"208","author":"BK Patel","year":"2017","unstructured":"Patel BK, Gray RJ, Pockaj BA (2017) Potential cost savings of contrast-enhanced digital mammography. AJR Am J Roentgenol 208:W231\u2013W237","journal-title":"AJR Am J Roentgenol"},{"key":"12633_CR13","doi-asserted-by":"publisher","first-page":"112315","DOI":"10.1016\/j.ejrad.2025.112315","volume":"191","author":"JA S\u00e1enz","year":"2025","unstructured":"S\u00e1enz JA, Baltzer PAT, Allajbeu I et al (2025) Overview of different reimbursement strategies among contrast-enhanced mammography (CEM) expert centers on a global level\u2014a survey study. Eur J Radiol 191:112315","journal-title":"Eur J Radiol"},{"key":"12633_CR14","doi-asserted-by":"publisher","first-page":"e240117","DOI":"10.1148\/rycan.240117","volume":"7","author":"L Pires-Gon\u00e7alves","year":"2025","unstructured":"Pires-Gon\u00e7alves L, Aguiar AT, Leal C, Guimar\u00e3es-Santos A, Abreu M, Henrique R (2025) Prospective evaluation of contrast-enhanced mammography for early prediction of pathologic response after neoadjuvant therapy. Radiol Imaging Cancer 7:e240117","journal-title":"Radiol Imaging Cancer"},{"key":"12633_CR15","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/02841851221144021","volume":"64","author":"L Pires-Gon\u00e7alves","year":"2023","unstructured":"Pires-Gon\u00e7alves L, Henriques Abreu M, Ferr\u00e3o A et al (2023) Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer. Acta Radiol 64:1816\u20131822","journal-title":"Acta Radiol"},{"key":"12633_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacr.2023.05.014","volume":"20","author":"WA Berg","year":"2023","unstructured":"Berg WA, Bandos AI, Sava MG (2023) Analytic hierarchy process analysis of patient preferences for contrast-enhanced mammography versus MRI as supplemental screening options for breast cancer. J Am Coll Radiol 20:758\u2013768","journal-title":"J Am Coll Radiol"},{"key":"12633_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7150\/jca.79747","volume":"14","author":"LMFH Neeter","year":"2023","unstructured":"Neeter LMFH, Robbe MMQ, van Nijnatten TJA et al (2023) Comparing the diagnostic performance of contrast-enhanced mammography and breast MRI: a systematic review and meta-analysis. J Cancer 14:174\u2013182","journal-title":"J Cancer"},{"key":"12633_CR18","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1007\/s00330-024-11195-4","volume":"35","author":"A Santonocito","year":"2025","unstructured":"Santonocito A, Zarcaro C, Zeitouni L et al (2025) A head-to-head comparison of breast lesion\u2019s conspicuity at contrast-enhanced mammography and contrast-enhanced MRI. Eur Radiol 35:3070\u20133079","journal-title":"Eur Radiol"},{"key":"12633_CR19","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1007\/s00330-025-11501-8","volume":"35","author":"I Allajbeu","year":"2025","unstructured":"Allajbeu I, Nanaa M, Manavaki R et al (2025) Improving the diagnostic performance of contrast-enhanced mammography through lesion conspicuity and enhancement quantification. Eur Radiol 35:6385\u20136397","journal-title":"Eur Radiol"},{"key":"12633_CR20","doi-asserted-by":"publisher","first-page":"109883","DOI":"10.1016\/j.ejrad.2021.109883","volume":"142","author":"MBI Lobbes","year":"2021","unstructured":"Lobbes MBI, Heuts EM, Moossdorff M, van Nijnatten TJA (2021) Contrast enhanced mammography (CEM) versus magnetic resonance imaging (MRI) for staging of breast cancer: the pro CEM perspective. Eur J Radiol 142:109883","journal-title":"Eur J Radiol"},{"key":"12633_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s11547-025-02009-8","volume":"130","author":"G Bicchierai","year":"2025","unstructured":"Bicchierai G, Migliaro G, Pugliese F et al (2025) Evaluation of contrast-enhanced mammography (CEM) in the preoperative staging of breast cancer: large-scale single center experience, update to 1005 cases. Radiol Med 130:830\u2013843","journal-title":"Radiol Med"},{"key":"12633_CR22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/diagnostics12081890","volume":"12","author":"F Gelardi","year":"2022","unstructured":"Gelardi F, Ragaini EM, Sollini M, Bernardi D, Chiti A (2022) Contrast-enhanced mammography versus breast magnetic resonance imaging: a systematic review and meta-analysis. Diagnostics (Basel) 12:1890","journal-title":"Diagnostics (Basel)"},{"key":"12633_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/diagnostics11030435","volume":"11","author":"V Iotti","year":"2021","unstructured":"Iotti V, Ragazzi M, Besutti G et al (2021) Accuracy and reproducibility of contrast-enhanced mammography in the assessment of response to neoadjuvant chemotherapy in breast cancer patients with calcifications in the tumor bed. Diagnostics (Basel) 11:435","journal-title":"Diagnostics (Basel)"},{"key":"12633_CR24","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3390\/cancers16152694","volume":"16","author":"S Vidali","year":"2024","unstructured":"Vidali S, Irmici G, Depretto C et al (2024) Performance of contrast-enhanced mammography (CEM) for monitoring neoadjuvant chemotherapy response among different breast cancer subtypes. Cancers (Basel) 16:2694","journal-title":"Cancers (Basel)"},{"key":"12633_CR25","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2214\/AJR.22.27756","volume":"219","author":"D Bernardi","year":"2022","unstructured":"Bernardi D, Vatteroni G, Acquaviva A et al (2022) Contrast-enhanced mammography versus MRI in the evaluation of neoadjuvant therapy response in patients with breast cancer: a prospective study. AJR Am J Roentgenol 219:884\u2013894","journal-title":"AJR Am J Roentgenol"},{"key":"12633_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s11547-025-02068-x","volume":"130","author":"S Wang","year":"2025","unstructured":"Wang S, Li J, Chen R et al (2025) Head\u2011to\u2011head comparison of contrast\u2011enhanced mammography and MRI in assessing the tumor response to neoadjuvant therapy in breast cancer: a prospective, multireader study. Radiol Med 130:1561\u20131574","journal-title":"Radiol Med"},{"key":"12633_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13244-019-0756-0","volume":"10","author":"M Zanardo","year":"2019","unstructured":"Zanardo M, Cozzi A, Trimboli RM et al (2019) Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review. Insights Imaging 10:76","journal-title":"Insights Imaging"},{"key":"12633_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10549-015-3421-4","volume":"151","author":"G Luengo-Gil","year":"2015","unstructured":"Luengo-Gil G, Gonz\u00e1lez-Billalabeitia E, Chaves-Benito A et al (2015) Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Res Treat 151:577\u2013587","journal-title":"Breast Cancer Res Treat"},{"key":"12633_CR29","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1530\/VB-21-0013","volume":"3","author":"M Mclaughlin","year":"2021","unstructured":"Mclaughlin M, Florida-James G, Ross M (2021) Breast cancer chemotherapy vascular toxicity: a review of mediating mechanisms and exercise as a potential therapeutic. Vasc Biol 3:R106\u2013R120","journal-title":"Vasc Biol"},{"key":"12633_CR30","doi-asserted-by":"publisher","first-page":"108701","DOI":"10.1016\/j.ejrad.2019.108701","volume":"120","author":"EMS Negr\u00e3o","year":"2019","unstructured":"Negr\u00e3o EMS, Souza JA, Marques EF, Bitencourt AGV (2019) Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol 120:108701","journal-title":"Eur J Radiol"},{"key":"12633_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"12633_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821","journal-title":"N Engl J Med"},{"key":"12633_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556\u2013567","journal-title":"N Engl J Med"},{"key":"12633_CR34","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981\u20131991","journal-title":"N Engl J Med"},{"key":"12633_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED et al (2018) Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1630\u20131640","journal-title":"Lancet Oncol"},{"key":"12633_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T et al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159\u2013182","journal-title":"Ann Oncol"},{"key":"12633_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0168-9","volume":"6","author":"M Dowsett","year":"2020","unstructured":"Dowsett M, Ellis MJ, Dixon JM et al (2020) Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer 6:21","journal-title":"NPJ Breast Cancer"},{"key":"12633_CR38","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers13040902","volume":"13","author":"F Lerebours","year":"2021","unstructured":"Lerebours F, Cabel L, Pierga JY (2021) Neoadjuvant endocrine therapy in breast cancer management: state of the art. Cancers (Basel) 13:902","journal-title":"Cancers (Basel)"},{"key":"12633_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-023-07034-7","volume":"202","author":"M Kaiyin","year":"2023","unstructured":"Kaiyin M, Lingling T, Leilei T, Wenjia L, Bin J (2023) Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat 202:1\u20139","journal-title":"Breast Cancer Res Treat"},{"key":"12633_CR40","doi-asserted-by":"publisher","first-page":"20200301","DOI":"10.1259\/bjr.20200301","volume":"93","author":"S Tang","year":"2020","unstructured":"Tang S, Xiang C, Yang Q (2020) The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. Br J Radiol 93:20200301","journal-title":"Br J Radiol"},{"key":"12633_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-023-06865-8","volume":"198","author":"MP Hogan","year":"2023","unstructured":"Hogan MP, Horvat JV, Ross DS et al (2023) Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment. Breast Cancer Res Treat 198:349\u2013359","journal-title":"Breast Cancer Res Treat"},{"key":"12633_CR42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1245\/s10434-018-6413-x","volume":"25","author":"BK Patel","year":"2018","unstructured":"Patel BK, Hilal T, Covington M et al (2018) Contrast-enhanced spectral mammography is comparable to MRI in the assessment of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol 25:1350\u20131356","journal-title":"Ann Surg Oncol"},{"key":"12633_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13058-017-0899-1","volume":"19","author":"V Iotti","year":"2017","unstructured":"Iotti V, Ravaioli S, Vacondio R et al (2017) Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast Cancer Res 19:106","journal-title":"Breast Cancer Res"},{"key":"12633_CR44","doi-asserted-by":"publisher","first-page":"8531916","DOI":"10.1155\/2018\/8531916","volume":"2018","author":"FR Barra","year":"2018","unstructured":"Barra FR, Sobrinho AB, Barra RR et al (2018) Contrast-enhanced mammography (CEM) for detecting residual disease after neoadjuvant chemotherapy: a comparison with breast magnetic resonance imaging (MRI). Biomed Res Int 2018:8531916","journal-title":"Biomed Res Int"},{"key":"12633_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.diii.2014.01.019","volume":"95","author":"FR Barra","year":"2014","unstructured":"Barra FR, Ribeiro AC, Mathieu OD, Rodrigues AC (2014) Dual-energy contrast-enhanced digital mammography: examination protocol. Diagn Interv Imaging 95:351\u2013352","journal-title":"Diagn Interv Imaging"},{"key":"12633_CR46","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11547-024-01813-y","volume":"129","author":"C Depretto","year":"2024","unstructured":"Depretto C, D\u2019Ascoli E, Della Pepa G et al (2024) Assessing the malignancy of suspicious breast microcalcifications: the role of contrast enhanced mammography. Radiol Med 129:855\u2013863","journal-title":"Radiol Med"},{"key":"12633_CR47","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.acra.2021.12.022","volume":"29","author":"G Bicchierai","year":"2022","unstructured":"Bicchierai G, Busoni S, Tortoli P et al (2022) Single center evaluation of comparative breast radiation dose of contrast enhanced digital mammography (CEDM), digital mammography (DM) and digital breast tomosynthesis (DBT). Acad Radiol 29:1342\u20131349","journal-title":"Acad Radiol"},{"key":"12633_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2214\/AJR.16.16743","volume":"208","author":"JR James","year":"2017","unstructured":"James JR, Pavlicek W, Hanson JA, Boltz TF, Patel BK (2017) Breast radiation dose with CESM compared with 2D FFDM and 3D tomosynthesis mammography. AJR Am J Roentgenol 208:362\u2013372","journal-title":"AJR Am J Roentgenol"},{"key":"12633_CR49","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2214\/AJR.17.19036","volume":"211","author":"J Phillips","year":"2018","unstructured":"Phillips J, Mihai G, Hassonjee SE et al (2018) Comparative dose of contrast-enhanced spectral mammography (CESM), digital mammography, and digital breast tomosynthesis. AJR Am J Roentgenol 211:839\u2013846","journal-title":"AJR Am J Roentgenol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12633-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:53:49Z","timestamp":1789379629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12633-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["12633"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12633-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Chiara Bellini.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relevant relationships with any companies whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Francesco Amato kindly provided statistical advice for this manuscript.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"103 study subjects have been previously reported in a previously published paper (\n                      \n                      ).","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}